Pediatrix Medical Group announces $250M share repurchase program with three-year term

Pediatrix Medical Group, Inc.

Board authorized up to $250M in share repurchases of outstanding common stock over three years.
CEO Mark Ordan cites strong cash flow, current cash balances, and low debt levels as rationale.
Repurchases may be made via open market or privately negotiated transactions, including 10b5-1 plans.
Program may be suspended or discontinued at any time; no obligation to repurchase any specific amount.
Company will weigh repurchases against other strategic uses of cash for long-term shareholder returns.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.